A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes two weeks after J&J ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Approval of Spravato, granted following FDA priority review, was based on the results of ... exhibited numerical improvements ...